Eli Lilly and Company (NYSE:LLY) is LGT Fund Management Co Ltd.’s 5th Largest Position

LGT Fund Management Co Ltd. increased its stake in Eli Lilly and Company (NYSE:LLY) by 4.4% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,520 shares of the company’s stock after acquiring an additional 400 shares during the period. Eli Lilly and Company makes up approximately 2.4% of LGT Fund Management Co Ltd.’s investment portfolio, making the stock its 5th biggest position. LGT Fund Management Co Ltd.’s holdings in Eli Lilly and Company were worth $5,530,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its position in shares of Eli Lilly and Company by 0.9% during the third quarter. Vanguard Group Inc. now owns 70,575,602 shares of the company’s stock valued at $37,908,273,000 after buying an additional 659,838 shares during the period. Morgan Stanley boosted its position in shares of Eli Lilly and Company by 0.7% during the third quarter. Morgan Stanley now owns 12,545,572 shares of the company’s stock valued at $6,738,605,000 after buying an additional 83,915 shares during the period. Northern Trust Corp boosted its position in shares of Eli Lilly and Company by 3.6% during the third quarter. Northern Trust Corp now owns 10,158,275 shares of the company’s stock valued at $5,456,314,000 after buying an additional 355,317 shares during the period. International Assets Investment Management LLC boosted its position in shares of Eli Lilly and Company by 61,268.8% during the fourth quarter. International Assets Investment Management LLC now owns 7,342,780 shares of the company’s stock valued at $42,802,530,000 after buying an additional 7,330,815 shares during the period. Finally, Charles Schwab Investment Management Inc. boosted its position in shares of Eli Lilly and Company by 2.0% during the third quarter. Charles Schwab Investment Management Inc. now owns 4,435,311 shares of the company’s stock valued at $2,382,339,000 after buying an additional 88,016 shares during the period. Hedge funds and other institutional investors own 82.53% of the company’s stock.

Eli Lilly and Company Stock Performance

Shares of LLY traded down $14.48 during trading hours on Thursday, reaching $762.27. 992,691 shares of the company traded hands, compared to its average volume of 3,041,964. The stock has a market capitalization of $724.28 billion, a P/E ratio of 113.06, a P/E/G ratio of 1.58 and a beta of 0.37. The company has a quick ratio of 0.73, a current ratio of 0.94 and a debt-to-equity ratio of 1.69. Eli Lilly and Company has a 12-month low of $414.31 and a 12-month high of $800.78. The business has a fifty day moving average price of $762.03 and a 200-day moving average price of $669.96.

Eli Lilly and Company (NYSE:LLY) last announced its quarterly earnings data on Tuesday, April 30th. The company reported $2.58 earnings per share for the quarter, beating analysts’ consensus estimates of $2.53 by $0.05. The firm had revenue of $8.77 billion for the quarter, compared to analyst estimates of $8.94 billion. Eli Lilly and Company had a net margin of 17.08% and a return on equity of 59.28%. The business’s quarterly revenue was up 26.0% compared to the same quarter last year. During the same period in the previous year, the company earned $1.62 earnings per share. Equities analysts anticipate that Eli Lilly and Company will post 13.5 EPS for the current fiscal year.

Analysts Set New Price Targets

LLY has been the subject of several research analyst reports. Truist Financial lifted their price target on shares of Eli Lilly and Company from $850.00 to $892.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. boosted their price objective on shares of Eli Lilly and Company from $850.00 to $900.00 and gave the stock an “overweight” rating in a research note on Wednesday. Cantor Fitzgerald reissued an “overweight” rating and issued a $885.00 price objective (up previously from $815.00) on shares of Eli Lilly and Company in a research note on Tuesday. Erste Group Bank raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, April 3rd. Finally, The Goldman Sachs Group upped their price target on Eli Lilly and Company from $650.00 to $723.00 and gave the stock a “neutral” rating in a research report on Thursday, April 11th. Three analysts have rated the stock with a hold rating and seventeen have assigned a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $757.95.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.